Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore, the article has been withdrawn.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/ editorial-policies-main.php.
Bentham science disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
{"title":"WITHDRAWN: Scrutinizing the Role of Genetically Modified\u0000Herbs (GMHs) in the Treatment of Various Diseases","authors":"Rakesh K Sindhu, Rishu Verma, Twinkle Salgotra, Piyush Madaan, Parteek Chandel, Gaber El-Saber Batiha, Simona Cavalu","doi":"10.2174/1872208316666220512113921","DOIUrl":"10.2174/1872208316666220512113921","url":null,"abstract":"<p><p>Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore,\u0000the article has been withdrawn.</p><p><p>Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.</p><p><p>The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/\u0000editorial-policies-main.php.</p><p><strong>Bentham science disclaimer: </strong>It is a condition of publication that manuscripts submitted to this journal have not been published and will\u0000not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or\u0000table that has been published elsewhere must be reported, and copyright permission for reproduction must\u0000be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree\u0000that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated\u0000information is discovered. By submitting a manuscript the authors agree that the copyright of their\u0000article is transferred to the publishers if and when the article is accepted for publication.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10788401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-15DOI: 10.2174/1872208316666220415124439
S. Kaur
BACKGROUND The orchids are popular as beautiful cut-flowers in floriculture trade world over. The current paper reviews factors affecting the in vitro flowering in orchid species. METHOD The phenomenon of in vitro flowering is advantageous as it shortens the breeding cycle, which is prolonged in the in vivo grown orchid species of commercial value. Certain genetic and biochemical mechanisms are involved at the time of onset of flowering in orchid plants. In the present endeavour, efforts have been made to initiate in vitro flowering in a terrestrial and epiphytic orchid species. Various phenomenon involved during transition of vegetative shoot apex into floral axis is also reviewed. RESULTS In vitro flowering was induced in Dendrobium nobile and Zeuxine strateumatica in Mitra medium supplemented with BAP at 0.5 in mgl-1. CONCLUSION In vitro flowering can be initiated by manipulating physical and chemical stimulus in the nutrient regime. The study would be helpful in better understanding the complex process of flowering in vitro as well as ex vitro.
{"title":"In vitro florigenesis with special reference to orchids- A Review.","authors":"S. Kaur","doi":"10.2174/1872208316666220415124439","DOIUrl":"https://doi.org/10.2174/1872208316666220415124439","url":null,"abstract":"BACKGROUND\u0000The orchids are popular as beautiful cut-flowers in floriculture trade world over. The current paper reviews factors affecting the in vitro flowering in orchid species.\u0000\u0000\u0000METHOD\u0000The phenomenon of in vitro flowering is advantageous as it shortens the breeding cycle, which is prolonged in the in vivo grown orchid species of commercial value. Certain genetic and biochemical mechanisms are involved at the time of onset of flowering in orchid plants. In the present endeavour, efforts have been made to initiate in vitro flowering in a terrestrial and epiphytic orchid species. Various phenomenon involved during transition of vegetative shoot apex into floral axis is also reviewed.\u0000\u0000\u0000RESULTS\u0000In vitro flowering was induced in Dendrobium nobile and Zeuxine strateumatica in Mitra medium supplemented with BAP at 0.5 in mgl-1.\u0000\u0000\u0000CONCLUSION\u0000In vitro flowering can be initiated by manipulating physical and chemical stimulus in the nutrient regime. The study would be helpful in better understanding the complex process of flowering in vitro as well as ex vitro.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46043030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-12DOI: 10.2174/1872208316666220412133749
M. H. Shahrajabian, Q. Cheng, Wenli Sun
Biostimulants which contain substances or products including natural compounds, special formulation and microorganisms have gained a considerable attention as sustainable method for heavy metal detoxification, stimulate natural toxins, controlling diseases and pests, may increase both water and nutrient efficiency. Biostimulants are important products in modern agriculture which composed of different heterogenous classes of compounds with a broad spectrum of action to increase both qualitative and quantitative productions. Amino acids can be useful in stress defence, photosynthesis, increase nutrient uptake, pollination and fruit formation, precursors to hormones and growth parameters. Amino acids are considered as precursors and constituents of proteins, which are well-known for stimulation of cell growth. Because, they are the basic building blocks of proteins, amino acids are very important in plant growth, development and metabolite synthesis. One of the diverse, notable and the large group of secondary metabolites is phenolic compounds which have important function in regulation of the plants physiological activities, oxidation-reduction processes and photosynthesis. Protein hydrolysates contain amino acids and peptides which is one of the most important kinds of biostimulants. Protein hydrolysates have notable capability to increase crop performance, particularly under environmental stress conditions. This review article is aimed to introduce and found more about the roles of different types of biostimulants on plant growth and final yield production with considering sustainable agriculture.
{"title":"The Effects of Amino acids, Phenols and Protein Hydrolysates as Biostimulants on Sustainable Crop Production and Alleviate Stresses.","authors":"M. H. Shahrajabian, Q. Cheng, Wenli Sun","doi":"10.2174/1872208316666220412133749","DOIUrl":"https://doi.org/10.2174/1872208316666220412133749","url":null,"abstract":"Biostimulants which contain substances or products including natural compounds, special formulation and microorganisms have gained a considerable attention as sustainable method for heavy metal detoxification, stimulate natural toxins, controlling diseases and pests, may increase both water and nutrient efficiency. Biostimulants are important products in modern agriculture which composed of different heterogenous classes of compounds with a broad spectrum of action to increase both qualitative and quantitative productions. Amino acids can be useful in stress defence, photosynthesis, increase nutrient uptake, pollination and fruit formation, precursors to hormones and growth parameters. Amino acids are considered as precursors and constituents of proteins, which are well-known for stimulation of cell growth. Because, they are the basic building blocks of proteins, amino acids are very important in plant growth, development and metabolite synthesis. One of the diverse, notable and the large group of secondary metabolites is phenolic compounds which have important function in regulation of the plants physiological activities, oxidation-reduction processes and photosynthesis. Protein hydrolysates contain amino acids and peptides which is one of the most important kinds of biostimulants. Protein hydrolysates have notable capability to increase crop performance, particularly under environmental stress conditions. This review article is aimed to introduce and found more about the roles of different types of biostimulants on plant growth and final yield production with considering sustainable agriculture.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48741587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-08DOI: 10.2174/1872208316666220408114129
L. D. Goyzueta-Mamani, Miguel Angel Chávez-Fumagalli, Karla L. Alvarez-Fernandez, J. Aguilar-Pineda, Rita Nieto-Montesinos, G. Davila Del-Carpio, K. J. Vera-López, C. L. Lino Cardenas
BACKGROUND Alzheimer's disease (AD) is characterized by cognitive impairment, tau protein deposits, and amyloid beta plaques. AD impacted 44 million people in 2016, and it is estimated to affect 100 million people by 2050. AD is disregarded as a pandemic compared with other diseases. To date, there is no effective treatment or diagnosis. OBJECTIVE We aimed to discuss the current tools used to diagnose COVID-19, to point out their potential to be adapted for AD diagnosis, and to review the landscape of existing patents in the AD field and future perspectives for AD diagnosis. METHOD We carried out a scientific screening following a research strategy in PubMed; Web of Science; the Derwent Innovation Index; the KCI-Korean Journal Database; SciELO; the Russian Science Citation index; and the CDerwent, EDerwent, and MDerwent index databases. RESULTS A total of 326 from 6,446 articles about AD and 376 from 4,595 articles about COVID-19 were analyzed. Of these, AD patents were focused on biomarkers and neuroimaging with no accurate, validated diagnostic methods, and only 7% of kit development patents were found. In comparison, COVID-19 patents were 60% about kit development for diagnosis; they are highly accurate and are now commercialized. CONCLUSION AD is still neglected and not recognized as a pandemic that affects the people and economies of all nations. There is a gap in the development of AD diagnostic tools that could be filled if the interest and effort that has been invested to tackle the COVID-19 emergency could also be applied for innovation.
背景:阿尔茨海默病(AD)以认知障碍、tau蛋白沉积和β淀粉样蛋白斑块为特征。2016年，阿尔茨海默病影响了4400万人，预计到2050年将影响1亿人。与其他疾病相比，AD被认为是一种大流行。迄今为止，尚无有效的治疗或诊断方法。目的探讨当前用于诊断新冠肺炎的工具，指出其用于AD诊断的潜力，并回顾AD领域现有专利的现状和AD诊断的未来前景。方法我们按照PubMed的研究策略进行科学筛选;Web of Science;德文特创新指数;KCI-Korean Journal Database;收录了;俄罗斯科学引文索引;以及CDerwent、EDerwent和MDerwent索引数据库。结果从有关AD的6446篇文献中共分析了326份，从有关COVID-19的4595篇文献中共分析了376份。其中，AD专利集中在生物标志物和神经影像学上，没有准确、有效的诊断方法，只有7%的试剂盒开发专利被发现。相比之下，COVID-19专利60%与诊断试剂盒开发有关;它们非常精确，现在已经商业化了。结论:艾滋病仍然被忽视，没有被认为是一种影响各国人民和经济的大流行病。如果将为应对新冠肺炎疫情投入的精力和兴趣也用于创新，就可以填补阿尔茨海默病诊断工具开发的空白。
{"title":"Alzheimer's Disease: A Silent Pandemic - A Systematic Review on the Situation and Patent Landscape of the Diagnosis.","authors":"L. D. Goyzueta-Mamani, Miguel Angel Chávez-Fumagalli, Karla L. Alvarez-Fernandez, J. Aguilar-Pineda, Rita Nieto-Montesinos, G. Davila Del-Carpio, K. J. Vera-López, C. L. Lino Cardenas","doi":"10.2174/1872208316666220408114129","DOIUrl":"https://doi.org/10.2174/1872208316666220408114129","url":null,"abstract":"BACKGROUND\u0000Alzheimer's disease (AD) is characterized by cognitive impairment, tau protein deposits, and amyloid beta plaques. AD impacted 44 million people in 2016, and it is estimated to affect 100 million people by 2050. AD is disregarded as a pandemic compared with other diseases. To date, there is no effective treatment or diagnosis.\u0000\u0000\u0000OBJECTIVE\u0000We aimed to discuss the current tools used to diagnose COVID-19, to point out their potential to be adapted for AD diagnosis, and to review the landscape of existing patents in the AD field and future perspectives for AD diagnosis.\u0000\u0000\u0000METHOD\u0000We carried out a scientific screening following a research strategy in PubMed; Web of Science; the Derwent Innovation Index; the KCI-Korean Journal Database; SciELO; the Russian Science Citation index; and the CDerwent, EDerwent, and MDerwent index databases.\u0000\u0000\u0000RESULTS\u0000A total of 326 from 6,446 articles about AD and 376 from 4,595 articles about COVID-19 were analyzed. Of these, AD patents were focused on biomarkers and neuroimaging with no accurate, validated diagnostic methods, and only 7% of kit development patents were found. In comparison, COVID-19 patents were 60% about kit development for diagnosis; they are highly accurate and are now commercialized.\u0000\u0000\u0000CONCLUSION\u0000AD is still neglected and not recognized as a pandemic that affects the people and economies of all nations. There is a gap in the development of AD diagnostic tools that could be filled if the interest and effort that has been invested to tackle the COVID-19 emergency could also be applied for innovation.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47014697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-08DOI: 10.2174/1872208316666220408113002
S. Datta, A. Roy
The severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has spread exponentially, leading to an alarming number of deaths worldwide. A devastating effect has been observed in susceptible populations. Our body's immune system plays a very important role in fighting against the diseases. The principle of herd immunity (also known as population immunity), which has found its way into science and has been in the limelight, is the most widely recognised among all. It is an indirect defence against infectious diseases when a community has gained immunity, either through vaccines or through prior infection. Herd immunity against COVID-19 must be achieved to reduce the transmission of disease and save lives. Therefore, this review provides a comprehension of the role of immunity, with a special emphasis on herd immunity against COVID-19, and the ways to attain herd immunity in India have also been discussed.
{"title":"Herd Immunity against Coronavirus: A Review.","authors":"S. Datta, A. Roy","doi":"10.2174/1872208316666220408113002","DOIUrl":"https://doi.org/10.2174/1872208316666220408113002","url":null,"abstract":"The severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has spread exponentially, leading to an alarming number of deaths worldwide. A devastating effect has been observed in susceptible populations. Our body's immune system plays a very important role in fighting against the diseases. The principle of herd immunity (also known as population immunity), which has found its way into science and has been in the limelight, is the most widely recognised among all. It is an indirect defence against infectious diseases when a community has gained immunity, either through vaccines or through prior infection. Herd immunity against COVID-19 must be achieved to reduce the transmission of disease and save lives. Therefore, this review provides a comprehension of the role of immunity, with a special emphasis on herd immunity against COVID-19, and the ways to attain herd immunity in India have also been discussed.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43563973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-04DOI: 10.2174/1872208316666220404103033
Rimple Kaul, S. Devi
Coronaviruses hold idiosyncratic morphological features and functionality. The members of this group have a remarkable capability of infecting both animals and humans. Inimitably, the replication of the RNA genome continues through the set of viral mRNA molecules. Coronaviruses received the least attention until 2003 since they caused only minor respiratory tract illnesses. However, this changed exclusively with the introduction of zoonotic SARS-CoV in 2003. In 2012, MERS-CoV emerged and confirmed this group of viruses as the major causative agents of severe respiratory tract illness. Today, Coronavirus Disease 2019 (i.e., COVID-19) has turned out to be a chief health problem that causes a severe acute respiratory disorder in humans. Since the first identification of COVID-19 in December 2019 in Wuhan, China, this infection has devastatingly spread all around the globe leading to a crippling affliction for humans. The strain is known as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and WHO (the World Health Organization) has termed this new pandemic disease as Coronavirus Disease (COVID-19). COVID-19 is still spreading, with an estimated 136 million confirmed cases and more than 2.94 million deaths worldwide so far while the pandemic is still going on. In the current scenario, there is no particular treatment for COVID-19, however remarkable efforts for immunization and vaccine development can be observed. Therefore, the execution of precautions and proper preventive measures are indispensable to minimize and control the community transmission of the virus. This review summarizes information about the pathophysiology, transmission, symptoms, and the host defense mechanism as well as immunization and vaccine development against COVID-19.
{"title":"Coronavirus-A Crippling Affliction to Humans.","authors":"Rimple Kaul, S. Devi","doi":"10.2174/1872208316666220404103033","DOIUrl":"https://doi.org/10.2174/1872208316666220404103033","url":null,"abstract":"Coronaviruses hold idiosyncratic morphological features and functionality. The members of this group have a remarkable capability of infecting both animals and humans. Inimitably, the replication of the RNA genome continues through the set of viral mRNA molecules. Coronaviruses received the least attention until 2003 since they caused only minor respiratory tract illnesses. However, this changed exclusively with the introduction of zoonotic SARS-CoV in 2003. In 2012, MERS-CoV emerged and confirmed this group of viruses as the major causative agents of severe respiratory tract illness. Today, Coronavirus Disease 2019 (i.e., COVID-19) has turned out to be a chief health problem that causes a severe acute respiratory disorder in humans. Since the first identification of COVID-19 in December 2019 in Wuhan, China, this infection has devastatingly spread all around the globe leading to a crippling affliction for humans. The strain is known as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and WHO (the World Health Organization) has termed this new pandemic disease as Coronavirus Disease (COVID-19). COVID-19 is still spreading, with an estimated 136 million confirmed cases and more than 2.94 million deaths worldwide so far while the pandemic is still going on. In the current scenario, there is no particular treatment for COVID-19, however remarkable efforts for immunization and vaccine development can be observed. Therefore, the execution of precautions and proper preventive measures are indispensable to minimize and control the community transmission of the virus. This review summarizes information about the pathophysiology, transmission, symptoms, and the host defense mechanism as well as immunization and vaccine development against COVID-19.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42392132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-01DOI: 10.2174/187220831601220408113712
E. Jirillo
Emilio Jirillo has been a full professor of immunology at the University of Bari Medical School (Bari, Italy) since 1986. His current fields of interest are mucosal immunity, microbial immunity, and immunonutrition. Especially in the field of immunonutrition, he has recently published in vitro and in vivo studies on the anti-inflammatory effects of polyphenols. He is the author of more than 560 papers, among which, 326 scientific papers are listed in PUBMED, including complete books and some chapters of books. He is the editor-in-chiefof Clinical Immunology Endocrine Metabolic Drugs and Endocrine Metabolic Immune Disorders-Drug Targets.
{"title":"Meet the Editorial Board Member","authors":"E. Jirillo","doi":"10.2174/187220831601220408113712","DOIUrl":"https://doi.org/10.2174/187220831601220408113712","url":null,"abstract":"Emilio Jirillo has been a full professor of immunology at the University of Bari Medical School (Bari, Italy) since 1986. His current fields of interest are mucosal immunity, microbial immunity, and immunonutrition. Especially in the field of immunonutrition, he has recently published in vitro and in vivo studies on the anti-inflammatory effects of polyphenols. He is the author of more than 560 papers, among which, 326 scientific papers are listed in PUBMED, including complete books and some chapters of books. He is the editor-in-chiefof Clinical Immunology Endocrine Metabolic Drugs and Endocrine Metabolic Immune Disorders-Drug Targets.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41509229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-03DOI: 10.2174/1872208316666220303095807
Rhaissa Coelho Andrade, Caroline Santana Figueredo, Janaína de Carvalho Alves, M. N. Roselino
BACKGROUND With the increase in cases of intolerance and allergies to milk protein, new food possibilities have been studied as an alternative to dairy drinks in order to meet the needs of this population, such as, non-dairy synbiotic drinks. OBJECTIVE The aim of this study was to carry out an integrative literature review on the main types of non-dairy synbiotic beverages, in order to investigate the probiotics and prebiotics added to them. Besides, we also looked into the characteristics of the substrates and fermentation conditions (temperature, time and pH), to assess the influences on bacterial viability, consumer acceptance, conservation and antimicrobial action. METHODS We conducted an integrative review of articles published on Pubmed, Web of Science, Scielo, Scopus and Capes journal in the last five years, using the following terms: symbiotic drink, symbiotic beverage, synbiotic drink, synbiotic beverage, bebida simbiótica, not kombucha, which after reading, resulted in the inclusion of 28 articles. RESULTS As expected, the main probiotics used were from the genera Lactobacillus and Bifidobacterium, and the prebiotics were inulin and fructooligosaccharide. It is noteworthy that all analyzed beverages were in fact probiotics since they obtained values above the minimum viability of 6 log CFU / mL, consequently, they can bring benefits to consumers. CONCLUSION Thus, beyond fruits and vegetables being rich sources of nutrients, they also enable the development of synbiotic drinks delivered from their substrates, being an alternative for the public with restrictions to milk.
背景随着对牛奶蛋白不耐受和过敏病例的增加，为了满足这一人群的需求，人们研究了新的食物替代乳制品饮料的可能性，例如非乳制品合生元饮料。目的本研究旨在对主要类型的非乳制品合生元饮料进行综合文献综述，以研究其添加的益生菌和益生元。此外，我们还研究了底物的特性和发酵条件（温度、时间和pH），以评估对细菌活力、消费者接受度、保存和抗菌作用的影响。方法我们对过去五年中发表在Pubmed、Web of Science、Scielo、Scopus和Capes杂志上的文章进行了综合综述，使用了以下术语：共生饮料、共生饮料、合生元饮料、合生元饮料、bebida simbiótica，而不是康普茶，经过阅读，共收录了28篇文章。结果预期使用的主要益生菌来自乳酸杆菌属和双歧杆菌属，益生元为菊粉和低聚果糖。值得注意的是，所有分析的饮料实际上都是益生菌，因为它们获得的值高于6 log CFU/mL的最低生存能力，因此，它们可以给消费者带来好处。结论因此，除了水果和蔬菜是丰富的营养来源外，它们还能够开发出从其基质中提供的合生元饮料，成为公众对牛奶有限制的替代品。
{"title":"Evidence and Updates on non-dairy synbiotic beverage development.","authors":"Rhaissa Coelho Andrade, Caroline Santana Figueredo, Janaína de Carvalho Alves, M. N. Roselino","doi":"10.2174/1872208316666220303095807","DOIUrl":"https://doi.org/10.2174/1872208316666220303095807","url":null,"abstract":"BACKGROUND\u0000With the increase in cases of intolerance and allergies to milk protein, new food possibilities have been studied as an alternative to dairy drinks in order to meet the needs of this population, such as, non-dairy synbiotic drinks.\u0000\u0000\u0000OBJECTIVE\u0000The aim of this study was to carry out an integrative literature review on the main types of non-dairy synbiotic beverages, in order to investigate the probiotics and prebiotics added to them. Besides, we also looked into the characteristics of the substrates and fermentation conditions (temperature, time and pH), to assess the influences on bacterial viability, consumer acceptance, conservation and antimicrobial action.\u0000\u0000\u0000METHODS\u0000We conducted an integrative review of articles published on Pubmed, Web of Science, Scielo, Scopus and Capes journal in the last five years, using the following terms: symbiotic drink, symbiotic beverage, synbiotic drink, synbiotic beverage, bebida simbiótica, not kombucha, which after reading, resulted in the inclusion of 28 articles.\u0000\u0000\u0000RESULTS\u0000As expected, the main probiotics used were from the genera Lactobacillus and Bifidobacterium, and the prebiotics were inulin and fructooligosaccharide. It is noteworthy that all analyzed beverages were in fact probiotics since they obtained values above the minimum viability of 6 log CFU / mL, consequently, they can bring benefits to consumers.\u0000\u0000\u0000CONCLUSION\u0000Thus, beyond fruits and vegetables being rich sources of nutrients, they also enable the development of synbiotic drinks delivered from their substrates, being an alternative for the public with restrictions to milk.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45997925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Extracellular vesicles derived from mesenchymal stromal cells (MSC-EVs) are gaining interest for medical purposes. The promising therapeutic effects exhibited in both preclinical and clinical studies suggest that they may become an alternative for certain applications to cell-based therapies, which are subjected to stricter regulations. The commercial exploitation of these candidates requires a proper patent strategy from both the industry and public research organizations. Here, we raise a global patent literature analysis to identify key players and therapeutic applications in the field. Our results show an increasing rate of patent publications since 2009, with Asia (specifically China) leading the patenting activity. The therapeutic use of MSC-EVs within patent literature covers a wide range of diseases, in which "Dermal and Wounds", "Neurology" and "Cardiovascular" are the main therapeutic areas. Moreover, most of these patents include "product-by-process" claims, since the therapeutic effects of MSC-EVs could be influenced by their manufacturing process. Our results follow scientific and clinical literature trends.
{"title":"Use of patent information to characterize trends in the therapeutic applications of extracellular vesicles derived from mesenchymal stem cells (MSC-EVs).","authors":"Ángela Ponce-Polo, Alvaro RitoréHidalgo, Arturo Argüello Martínez, Roke Iñaki Oruezabal Guijarro","doi":"10.2174/1872208316666220303095217","DOIUrl":"https://doi.org/10.2174/1872208316666220303095217","url":null,"abstract":"Extracellular vesicles derived from mesenchymal stromal cells (MSC-EVs) are gaining interest for medical purposes. The promising therapeutic effects exhibited in both preclinical and clinical studies suggest that they may become an alternative for certain applications to cell-based therapies, which are subjected to stricter regulations. The commercial exploitation of these candidates requires a proper patent strategy from both the industry and public research organizations. Here, we raise a global patent literature analysis to identify key players and therapeutic applications in the field. Our results show an increasing rate of patent publications since 2009, with Asia (specifically China) leading the patenting activity. The therapeutic use of MSC-EVs within patent literature covers a wide range of diseases, in which \"Dermal and Wounds\", \"Neurology\" and \"Cardiovascular\" are the main therapeutic areas. Moreover, most of these patents include \"product-by-process\" claims, since the therapeutic effects of MSC-EVs could be influenced by their manufacturing process. Our results follow scientific and clinical literature trends.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47944454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-02DOI: 10.2174/1872208316666220302115901
Mohammad Saeedi, F. Mehranfar
Alzheimer's disease (AD) is a kinds of neuropsychiatric illnesses that affect the central nervous system. In this disease, the accumulation of amyloid-beta increases, and phosphorylated tau (P-tau) protein, one of the ways to treat this disease is to reduce the accumulation of amyloid-beta. Various studies have demonstrated that pharmacological approaches have considerable effects in the treatment of AD, despite the side effects and challenges. Cholinesterase inhibitors and the NMDA receptor antagonist memantine are presently authorized therapies for AD. Memantine and Donepezil are the most common drugs for the prevention and therapy of AD with mechanisms such as lessened β-amyloid plaque, effect on N-Methyl-D-aspartate (NMDA) receptors. Diminution glutamate and elevated acetylcholine are some of the influences of medications administrated to treat AD, and drugs can also play a role in slowing the progression of cognitive and memory impairment. A new pharmacological approach and strategy is required to control the future of AD. This review appraises the effects of memantine, donepezil, rivastigmine, and aducanumab in clinical trials, in vitro and animal model studies that have explored how these drugs versus AD development and also discuss possible mechanisms of influence on the brain. Research in clinical trials has substantial findings that support the role of these medications in AD treatment and ameliorate the safety and efficacy of AD therapy, although more clinical trials are required to prove their effectiveness.
阿尔茨海默病(Alzheimer's disease, AD)是一种影响中枢神经系统的神经精神疾病。在这种疾病中，淀粉样蛋白- β的积累增加，并磷酸化tau (P-tau)蛋白，治疗这种疾病的方法之一是减少淀粉样蛋白- β的积累。各种研究表明，尽管存在副作用和挑战，但药物方法在治疗AD方面具有相当大的效果。胆碱酯酶抑制剂和NMDA受体拮抗剂美金刚目前被批准用于治疗阿尔茨海默病。美金刚和多奈哌齐是预防和治疗AD最常用的药物，其机制包括减少β-淀粉样斑块，影响n -甲基- d -天冬氨酸(NMDA)受体。谷氨酸减少和乙酰胆碱升高是治疗阿尔茨海默病的药物的一些影响，药物也可以在减缓认知和记忆障碍的进展中发挥作用。需要一种新的药理学方法和策略来控制AD的未来。本综述评估了美金刚、多奈哌齐、利瓦司明和阿杜坎单抗在临床试验、体外和动物模型研究中的作用，探讨了这些药物如何对抗AD的发展，并讨论了对大脑的可能影响机制。临床试验研究已经有了实质性的发现，支持这些药物在阿尔茨海默病治疗中的作用，改善了阿尔茨海默病治疗的安全性和有效性，尽管需要更多的临床试验来证明它们的有效性。
{"title":"Challenges and approaches of drugs such as Memantine, Donepezil, Rivastigmine and Aducanumab in the treatment, control and management of Alzheimer's disease.","authors":"Mohammad Saeedi, F. Mehranfar","doi":"10.2174/1872208316666220302115901","DOIUrl":"https://doi.org/10.2174/1872208316666220302115901","url":null,"abstract":"Alzheimer's disease (AD) is a kinds of neuropsychiatric illnesses that affect the central nervous system. In this disease, the accumulation of amyloid-beta increases, and phosphorylated tau (P-tau) protein, one of the ways to treat this disease is to reduce the accumulation of amyloid-beta. Various studies have demonstrated that pharmacological approaches have considerable effects in the treatment of AD, despite the side effects and challenges. Cholinesterase inhibitors and the NMDA receptor antagonist memantine are presently authorized therapies for AD. Memantine and Donepezil are the most common drugs for the prevention and therapy of AD with mechanisms such as lessened β-amyloid plaque, effect on N-Methyl-D-aspartate (NMDA) receptors. Diminution glutamate and elevated acetylcholine are some of the influences of medications administrated to treat AD, and drugs can also play a role in slowing the progression of cognitive and memory impairment. A new pharmacological approach and strategy is required to control the future of AD. This review appraises the effects of memantine, donepezil, rivastigmine, and aducanumab in clinical trials, in vitro and animal model studies that have explored how these drugs versus AD development and also discuss possible mechanisms of influence on the brain. Research in clinical trials has substantial findings that support the role of these medications in AD treatment and ameliorate the safety and efficacy of AD therapy, although more clinical trials are required to prove their effectiveness.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47012328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号